iPS Cells & Regenerative Medicine– category –
-
3D Bioprinting Innovator Partners with MedTech Giant to Commercialize Regenerative Therapies
Specialized Media / Company Announcement USA Overview A pioneering 3D bioprinting company has announced a strategic licensing agreement with a leading medical device manufacturer, targeting the regenerative medicine sector. This partners... -
BioCentury Analyzes Commercialization Strategies for Gene-Edited Hematopoietic Stem Cell Therapies, Discussing Solutions for High Costs and Manufacturing Complexity
BioCentury USA Overview BioCentury published an analytical article focusing on commercialization strategies for companies developing gene-edited hematopoietic stem cell (HSC) therapies. The article discusses high treatment costs, manufac... -
ClinicalTrials.gov Updates Phase 2 Trial Registration for iPSC-Derived Retinal Pigment Epithelium Cell Transplantation for Age-Related Macular Degeneration
ClinicalTrials.gov USA Overview Information regarding a Phase 2 clinical trial for iPSC-derived Retinal Pigment Epithelium (RPE) cell transplantation targeting Age-related Macular Degeneration (AMD) has been updated or newly registered o... -
Japan’s Reprocell and University Announce Joint Development of iPSC Differentiation Protocol, Enhancing Cell Therapy Product Uniformity and Scalability
Reprocell / University Announcement Japan Overview Japanese regenerative medicine company Reprocell, in collaboration with a prominent university research lab, announced the joint development of a novel protocol for high-efficiency diffe... -
Exosome Therapeutics Firm Unveils Advanced Platform, Pipeline Progress Targeting Regenerative Medicine and Enhanced Drug Delivery
Company Disclosures USA Overview An exosome-based therapeutics company has detailed significant pipeline advancements and its cutting-edge technology platform at a recent investor briefing. The presentation particularly emphasized exosom... -
Automated GMP Facility Launched, Supercharging Scalable Production for Off-the-Shelf Cell Therapies
Company Announcement / Specialized Media International Overview A new, state-of-the-art GMP facility dedicated to commercial-scale allogeneic cell therapy manufacturing has commenced operations. This facility leverages advanced automatio... -
Pharma Giant Acquires Gene-Editing Pioneer, Bolstering Pipeline and Redefining R&D
Specialized Media USA Overview A leading pharmaceutical company has acquired a smaller biotechnology firm specializing in innovative gene-editing platforms. This strategic move aims to integrate cutting-edge gene therapy modalities into ... -
FDA Bestows RMAT Status on iPSC-Derived Cell Therapy for Intractable Disease, Poised to Accelerate Clinical Development
Company Announcement / Specialized Media USA Overview A regenerative medicine firm has announced its iPSC-derived cell therapy program for an intractable disease has received Regenerative Medicine Advanced Therapy (RMAT) designation from... -
FDA Issues Draft Guidance for Long-Term Follow-Up of Gene Therapies, Establishing Industry Standards for Safety and Efficacy
STAT News USA Overview The U.S. Food and Drug Administration (FDA) has released new draft guidance for the long-term safety and efficacy follow-up of approved gene therapy products. This guidance aims to establish industry standards for ... -
BioPharma Dive Features Real-World Evidence Analysis of Approved CAR-T Therapies, Unveiling New Insights into Subgroup Efficacy and Long-Term Safety
BioPharma Dive USA Overview BioPharma Dive published an in-depth analysis of post-market real-world data for approved CAR-T cell therapies. The article reveals novel insights into efficacy within specific patient subgroups and the long-t...
